CTLA4 and cancer: In several cancers, including melanoma, head and neck, and prostate tumors, EZH2 inhibition is associated with increased tumor immunogenicity and enhanced responsiveness to CTLA-4 or PD-1/PD-L1 blockade [177,178,179].